VEGF-B gene therapy inhibits doxorubicin-induced cardiotoxicity by endothelial protection.
about
A computational analysis of in vivo VEGFR activation by multiple co-expressed ligands.VEGFB-VEGFR1 ameliorates Ang II-induced cardiomyocyte hypertrophy through Ca(2+) -mediated PKG I pathway.Role of free fatty acids in endothelial dysfunction.Oral administration of Ginsenoside Rg1 prevents cardiac toxicity induced by doxorubicin in mice through anti-apoptosis.Prevention of chemotherapy-induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle.Sulforaphane protection against the development of doxorubicin-induced chronic heart failure is associated with Nrf2 Upregulation.Integrated approaches to spatiotemporally directing angiogenesis in host and engineered tissues.Genetic and ethnic modulation of cardiovascular toxicity of vascular endothelial growth factor inhibitors.Type IIB DNA topoisomerase is downregulated by trastuzumab and doxorubicin to synergize cardiotoxicity.Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective.Developing a Reliable Mouse Model for Cancer Therapy-Induced Cardiovascular Toxicity in Cancer Patients and Survivors.Chemotherapeutic-Induced Cardiovascular Dysfunction: Physiological Effects, Early Detection-The Role of Telomerase to Counteract Mitochondrial Defects and Oxidative Stress.Vascular Endothelial Growth Factor B and Its Signaling.Cardiotoxicity with vascular endothelial growth factor inhibitor therapy
P2860
Q36314931-8F01BA47-1F77-41A7-AD02-E08E7B2AB947Q38695797-8D1B097C-37F3-4EA1-AB01-E9590FE61399Q41147225-5EABC1E1-494D-4043-955B-52500D205B8FQ47101716-42417FDE-4EC8-49D5-8324-DD598C8FB966Q47303605-0A292B35-541E-47DE-88D4-C1B329EBDA43Q48245077-C1171662-CD64-4A3B-AF06-CD554AEA1D21Q49684144-408E8478-BB26-4FCD-B0F6-6318BA3D2C4FQ49997360-93338B9F-76AC-4328-93BB-677B68BD82DAQ50060140-556F1119-0488-44A9-B3F5-86B5C297CCD3Q51760757-4C49009D-65E7-4ECE-A989-16A02F0BC674Q54941414-7FDB17C3-3465-4F31-96D8-FFE51B0B40AAQ54959206-ACB41AC0-965E-4269-831D-34C2376FE44FQ55379904-2EA6D13C-61B2-4546-A4DA-E4F20F081FE0Q56991273-D427B0FF-5839-4DB4-9A57-3D3DEF2D22C5
P2860
VEGF-B gene therapy inhibits doxorubicin-induced cardiotoxicity by endothelial protection.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 October 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
VEGF-B gene therapy inhibits d ...... ity by endothelial protection.
@en
VEGF-B gene therapy inhibits d ...... ity by endothelial protection.
@nl
type
label
VEGF-B gene therapy inhibits d ...... ity by endothelial protection.
@en
VEGF-B gene therapy inhibits d ...... ity by endothelial protection.
@nl
prefLabel
VEGF-B gene therapy inhibits d ...... ity by endothelial protection.
@en
VEGF-B gene therapy inhibits d ...... ity by endothelial protection.
@nl
P2093
P2860
P50
P356
P1476
VEGF-B gene therapy inhibits d ...... ity by endothelial protection.
@en
P2093
Antti Siltanen
Eero Mervaala
Ilkka Miinalainen
Joni Degerman
Markus Räsänen
Risto Kerkelä
Tuuli A Nissinen
P2860
P304
13144-13149
P356
10.1073/PNAS.1616168113
P407
P577
2016-10-31T00:00:00Z